Baker Hughes also provides subsea and surface wellheads, pressure control and production systems and services, flexible pipe systems for offshore and onshore applications, and life-of-field solutions, including well intervention and decommissioning solutions, as well as services related to onshore and offshore drilling and production operations. In addition, the company offers equipment and related services for mechanical-drive, compression and power-generation applications across the oil and gas industry. Its product portfolio includes drivers, compressors and turnkey solutions, as well as pumps, valves and compressed natural gas and small-scale liquefied natural gas solutions.
Further, the company provides sensor-based process measurements, machine health and condition monitoring, asset strategy and management, control systems, as well as non-destructive testing and inspection and pipeline integrity solutions. Baker Hughes serves upstream, midstream, downstream, onshore, offshore and industrial customers.
Investors receive a 2.69% dividend. Jefferies has set a $36 price target, while the consensus target for Baker Hughes stock is $33.79. Wednesday’s closing print was $29.35.
Dexcom
This stock has been on a roll and looks to have more upside potential. Dexcom Inc. (NASDAQ: DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
The company provides its systems for use by people with diabetes, as well as for use by health care providers. Its products include Dexcom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, which is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
The Dexcom products candidature includes Dexcom G7, a next-generation G7 CGM system. Dexcom has a collaboration and license agreement with Verily Life Sciences and Verily Ireland to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians and diabetes educators.
The Jefferies price target is $135, and the consensus target is $129.29. Dexcom stock closed on Wednesday at $114.76.
Estee Lauder
With the holidays in full swing, shares of this long-time fragrance producer have some outstanding upside potential. Estee Lauder Companies Inc. (NYSE: EL) manufactures, markets and sells skincare, makeup, fragrance and hair care products worldwide.
The company offers a range of skincare products, including moisturizers, serums, cleansers, toners, body care, exfoliators, acne care and oil correctors, facial masks, cleansing devices, and sun care products. Its makeup products include lipsticks, lip glosses, mascaras, foundations, eyeshadows, nail polishes and powders, as well as compacts, brushes and other makeup tools.
It also provides fragrance products in various forms, comprising eau de parfum sprays and colognes, as well as lotions, powders, creams, candles and soaps. Its hair care products include shampoos, conditioners, styling products, treatment, finishing sprays and hair color products, and it sells ancillary products and services.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
